Akoya Biosciences, Inc.

NasdaqGS:AKYA Stock Report

Market Cap: US$123.4m

Akoya Biosciences Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of AKYA?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders2,600,9705.25%
Hedge Funds4,697,7859.48%
General Public8,035,55916.2%
Institutions8,158,00616.5%
VC/PE Firms26,071,06652.6%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 81.63% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
35.7%
Telegraph Hill Partners
17,675,247US$44.0m0%14.17%
9.84%
aMoon Fund
4,878,459US$12.1m58.5%22.1%
9.48%
Blue Water Life Science Advisors, LP
4,697,785US$11.7m0%10.18%
7.1%
PS Capital Partners, LLC
3,517,360US$8.8m0%no data
3.19%
BlackRock, Inc.
1,580,164US$3.9m5.21%no data
3%
The Vanguard Group, Inc.
1,484,973US$3.7m1.44%no data
1.99%
Matthew Winkler
984,513US$2.5m0%no data
1.59%
Paragon Associates, Ltd.
790,000US$2.0m126%3.72%
1.24%
Garry Nolan
616,913US$1.5m0%no data
1.13%
Geode Capital Management, LLC
561,609US$1.4m-0.09%no data
1.04%
SVB Wealth LLC
515,317US$1.3m0%0.02%
0.91%
State Street Global Advisors, Inc.
453,296US$1.1m4.22%no data
0.76%
Parkman Healthcare Partners LLC
376,131US$936.6k0.16%0.13%
0.75%
Robert Shepler
369,592US$920.3k0%no data
0.63%
GSA Capital Partners LLP
310,669US$773.6k87.4%0.06%
0.55%
Schonfeld Strategic Advisors LLC
271,400US$675.8k-7.79%0.01%
0.47%
Peddock Capital Advisors, LLC
234,720US$584.5k-0.09%0.14%
0.47%
Thomas Raffin
234,592US$584.1k0%no data
0.42%
Northern Trust Global Investments
210,544US$524.3k0.39%no data
0.29%
Caspar Towarzystwo Funduszy Inwestycyjnych S.A.
146,000US$363.5k0%2.14%
0.29%
Niro Ramachandran
144,799US$360.6k0%no data
0.25%
Osterweis Capital Management, Inc.
126,131US$314.1k0%0.02%
0.21%
Bridgeway Capital Management, LLC
105,600US$262.9k-41.2%no data
0.19%
Eaton Vance Management
92,362US$230.0k21.6%no data
0.17%
Pascal Bamford
82,758US$206.1k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 10:22
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Akoya Biosciences, Inc. is covered by 10 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mark MassaroBTIG
Kyle MiksonCanaccord Genuity
Timothy ChiangCapital One Securities, Inc.